A drug called ibrutinib that has been approved to treat chronic lymphocytic leukemia (CLL) was found to be less effective in some subset of patients, reveals a new study.
The study done by a team of researchers in Italy and Austria was published in the Journal of Experimental Medicine, reveals that ibrutinib has a diminished capacity to delocalize and kill tumor cells expressing an adhesive protein called CD49d, but combining ibrutinib treatment with drugs that block CD49d activation could prevent the tumor cells from sheltering in lymphoid organs.
Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia (CLL) is one of the most common types of adult leukemia and is considered as one of the 'good cancers'.
Advertisement
‘Combining ibrutinib with drugs that block CD49d activation can help prevent tumor cells and improves outcome in chronic lymphocytic leukemia (CLL) patients.’
Tweet it Now
CLL is the most common leukemia in adults, and it is characterized by the presence of cancerous B cells that accumulate in the lymph nodes, spleen, and liver.
Ibrutinib reallocates CLL cells from lymph nodes into the blood by inhibiting Bruton's tyrosine kinase (BTK), a key enzyme in the B cell receptor (BCR) signaling pathway.
![Non-Hodgkins Lymphoma]( "Non-Hodgkins Lymphoma")
Non Hodgkins Lymphoma is a cancer that affects the lymph tissues. It is made up of a wide array of subtypes.
BCR signaling promotes the survival and differentiation of normal, healthy B cells in several ways, including by activating the adhesion receptor VLA-4, which attaches B cells to other, supportive cells within lymph nodes.
One of the subunits of VLA-4, CD49d, is highly expressed in about 40% of CLL patients. These patients tend to have poorer outcomes than patients that do not express CD49d, but the role of VLA-4 in CLL is unclear.
A team of researchers led by Antonella Zucchetto and Valter Gattei of the CRO Aviano National Cancer Institute in Italy and Tanja Nicole Hartmann of the Paracelsus Medical University in Salzburg, Austria, found that BCR signaling can activate VLA-4 in CD49d-expressing CLL cells, thereby enhancing the cells' adhesiveness.
Even though ibrutinib treatment impaired BCR signaling in these cells, it was unable to fully hinder the pathway from activating VLA-4 and enhancing cell adhesion.
The researchers analyzed three different cohorts of CLL patients from Italy and the United States. In all three groups, patients expressing higher levels of CD49d showed reduced responses to ibrutinib treatment: the drug appeared to be less able to displace tumor cells from lymph nodes into the blood, resulting in decreased lymph node shrinkage and shorter progression-free survival times.
"Our results suggest that VLA-4-expressing CLL cells residing in the secondary lymphoid organs can receive BCR-mediated stimuli that can activate VLA-4 even in the presence of ibrutinib," says Zucchetto. "This activation leads to enhanced retention of VLA-4-positive CLL cells in tissue sites, thereby affecting patient outcome."
In addition to the ibrutinib target BTK, BCR signaling can proceed through an alternative enzyme called phosphatidylinositide 3-kinase. The researchers found that simultaneously inhibiting both BTK and phosphatidylinositide 3-kinase completely blocked VLA-4 activation in CLL cells.
"Our data suggest that evaluation of CD49d expression in patients initiating ibrutinib therapy may identify those cases that would benefit from combination therapy approaches designed to completely block VLA-4 activation and VLA-4-mediated retention of leukemic cells in protective tissue compartments," says Gattei.
Source: Eurekalert
Non-Hodgkins Lymphoma
Non Hodgkins Lymphoma is a cancer that affects the lymph tissues. It is made up of a wide array of subtypes.
Advertisement
BCR signaling promotes the survival and differentiation of normal, healthy B cells in several ways, including by activating the adhesion receptor VLA-4, which attaches B cells to other, supportive cells within lymph nodes.
One of the subunits of VLA-4, CD49d, is highly expressed in about 40% of CLL patients. These patients tend to have poorer outcomes than patients that do not express CD49d, but the role of VLA-4 in CLL is unclear.
A team of researchers led by Antonella Zucchetto and Valter Gattei of the CRO Aviano National Cancer Institute in Italy and Tanja Nicole Hartmann of the Paracelsus Medical University in Salzburg, Austria, found that BCR signaling can activate VLA-4 in CD49d-expressing CLL cells, thereby enhancing the cells' adhesiveness.
Even though ibrutinib treatment impaired BCR signaling in these cells, it was unable to fully hinder the pathway from activating VLA-4 and enhancing cell adhesion.
The researchers analyzed three different cohorts of CLL patients from Italy and the United States. In all three groups, patients expressing higher levels of CD49d showed reduced responses to ibrutinib treatment: the drug appeared to be less able to displace tumor cells from lymph nodes into the blood, resulting in decreased lymph node shrinkage and shorter progression-free survival times.
"Our results suggest that VLA-4-expressing CLL cells residing in the secondary lymphoid organs can receive BCR-mediated stimuli that can activate VLA-4 even in the presence of ibrutinib," says Zucchetto. "This activation leads to enhanced retention of VLA-4-positive CLL cells in tissue sites, thereby affecting patient outcome."
In addition to the ibrutinib target BTK, BCR signaling can proceed through an alternative enzyme called phosphatidylinositide 3-kinase. The researchers found that simultaneously inhibiting both BTK and phosphatidylinositide 3-kinase completely blocked VLA-4 activation in CLL cells.
"Our data suggest that evaluation of CD49d expression in patients initiating ibrutinib therapy may identify those cases that would benefit from combination therapy approaches designed to completely block VLA-4 activation and VLA-4-mediated retention of leukemic cells in protective tissue compartments," says Gattei.
Source: Eurekalert
MicroRNA-TP53 Circuit Linked to Chronic Lymphocytic Leukemia
The interplay between a major tumor-suppressing gene, a truncated chromosome and two sets of microRNAs provides a molecular basis for the less aggressive form of CLL.
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Cancer News
The combination of the personalized cancer vaccine with ACT led to ovarian cancer control in few patients within a span of three months, stated study results.
Uncovering key kinases in tumor growth and invasion is crucial for improving targeted therapies in advanced-stage colorectal cancer.
The study findings validate metal-enhanced photo-oxidation for future metal-based anticancer drugs.
Mutations in 11 genes are linked to aggressive forms of prostate cancer, which may present novel therapeutic and therapy options.
Improved oral health, as indicated by the count of natural teeth and dental appointments preceding the diagnosis, correlated with enhanced head and neck cancer survival rates.
